Investors' expectations are high that Akeso and Summit Therapeutics' ivonescimab could eventually best Merck's Keytruda in overall survival for the first-line treatment of PD-L1-positive non-small cell lung cancer. (Shutterstock)
Keep up with the top pharma business news of the week. On the go.
